5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
Csf1r antibody
Manufactured by BioXCell
The CSF1R antibody is a laboratory tool used to detect and study the expression of the colony-stimulating factor 1 receptor (CSF1R) protein in biological samples. CSF1R is a receptor tyrosine kinase that plays a key role in the regulation of macrophage development and function. The CSF1R antibody can be used in various applications, such as Western blotting, immunohistochemistry, and flow cytometry, to analyze the presence and distribution of CSF1R in cells and tissues.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using csf1r antibody
1
Tumor Immunotherapy Protocol in Mice
2
Tumor Immunotherapy Protocol in Mice
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
5×105 tumor cells were injected s.c. into mice, which formed tumors with a 1.5-cm diameter within 2–3 weeks of injection. Lipofermata was administrated s.c. at dose of 2 mg/kg twice per day. As a control, mice were treated with vehicle alone (DMSO + 30% v/v Kolliphor). Treatments with lipofermata started 8–10 days after tumors injections. CSF1R antibody (BioXcell, 300 μg/mouse) was administered every other day starting next day after tumor injection and continued until the mice were sacrificed. PD-1 antibody (clone RMP1–14, BioXcell, 200 μg/mouse) was administered twice a week started 10–12 days after tumor injection. CTLA4-IgG2a (BioXcell, 200 μg/mouse) was administered at day 7 and day 11.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!